Sionna Therapeutics (NASDAQ:SION) Reaches New 52-Week High – Here’s What Happened

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) hit a new 52-week high on Monday . The company traded as high as $45.00 and last traded at $44.21, with a volume of 5187 shares traded. The stock had previously closed at $43.70.

Wall Street Analysts Forecast Growth

SION has been the topic of a number of recent research reports. Raymond James Financial reissued a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday. BTIG Research assumed coverage on shares of Sionna Therapeutics in a research note on Wednesday, November 19th. They set a “buy” rating and a $50.00 price target for the company. Finally, Lifesci Capital started coverage on shares of Sionna Therapeutics in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Sionna Therapeutics Stock Performance

The stock has a market cap of $1.85 billion and a P/E ratio of -8.50. The firm’s fifty day simple moving average is $40.24 and its 200-day simple moving average is $28.71.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06.

Insider Transactions at Sionna Therapeutics

In related news, Director Orbimed Advisors Llc sold 33,356 shares of the company’s stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total transaction of $1,486,009.80. Following the sale, the director owned 3,561,655 shares in the company, valued at $158,671,730.25. This represents a 0.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Peter A. Thompson sold 33,356 shares of Sionna Therapeutics stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 1,571,610 shares of company stock valued at $58,355,629. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics during the 3rd quarter valued at $30,000. BNP Paribas Financial Markets acquired a new position in shares of Sionna Therapeutics during the second quarter valued at about $31,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Sionna Therapeutics during the 2nd quarter worth about $45,000. Virtus Investment Advisers LLC acquired a new stake in shares of Sionna Therapeutics in the 2nd quarter valued at about $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Sionna Therapeutics in the 2nd quarter valued at about $117,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.